The UK MND Clinical Studies Group, having reviewed the available evidence on the efficacy of edaravone, has agreed the following Position Statement:
The CSG believes a properly designed, randomised placebo-controlled phase 3 trial of oral edaravone is required to determine the treatment’s efficacy.  UK MND CSG – oral edaravone position statement